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SUMMARY
Toxoplasma gondii is an obligate intracellular protozoan parasite of the phylum Apicomplexa, and toxoplasmosis is an
important disease of both humans and economically important animals. With a limited array of drugs available there is
a need to identify new therapeutic compounds. Aureobasidin A (AbA) is an antifungal that targets the essential inositol
phosphorylceramide (IPC, sphingolipid) synthase in pathogenic fungi. This natural cyclic depsipeptide also inhibits
Toxoplasma proliforation, with the protozoan IPC synthase orthologue proposed as the target. The data presented here
show that neither AbA nor an analogue (Compound 20), target the protozoan IPC synthase orthologue or total parasite
sphingolipid synthesis. However, further analyses conﬁrm that AbA exhibits signiﬁcant activity against the proliferative
tachyzoite form ofToxoplasma, and Compound 20, whilst eﬀective, has reduced eﬃcacy. This diﬀerence was more evident
on analyses of the direct eﬀect of these compounds against isolated Toxoplasma, indicating that AbA is rapidly microbi-
cidal. Importantly, the possibility of targeting the encysted, bradyzoite, form of the parasite with AbA and Compound 20
was demonstrated, indicating that this class of compounds may provide the basis for the ﬁrst eﬀective treatment for chronic
toxoplasmosis.
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INTRODUCTION
Aureobasidin A (AbA; Fig. 1) is a cyclic depsipep-
tide antifungal antibiotic isolated from the fungus
Aureobasidium pullulans R106 (Ikai et al. 1991;
Takesako et al. 1991). Resistance in Saccharomycin
cerevisiae was found to be conferred by dominant
negative mutations in the Aureobasidin resistance
(AUR1) gene (Heidler and Radding, 1995).
Subsequently, AUR1 was identiﬁed as encoding
the essential inositol phosphorylceramide (IPC) syn-
thase activity in fungi (Nagiec et al. 1997). AbA has
been shown to be an irreversible inhibitor of
the S. cerevisiae IPC synthase, acting in a time
dependant manner (Aeed et al. 2009), with the
toxic eﬀects associated with both a build up of the
bioactive substrate ceramide and the deprivation of
IPC (Cerantola et al. 2009). Recent eﬀorts have
utilized a semi-synthetic approach to generate analo-
gues of AbA which demonstrate improved activity
against some pathogenic fungal species, for example
Aspirgillus fumigatus (Wuts et al. 2015).
IPC is an essential sphingolipid found in fungi,
plants and some protozoa (Young et al. 2012). In
contrast, mammals lack IPC and instead synthesize
sphingomyelin (SM) as their major sphingolipid
species using SM synthase (Huitema et al. 2004).
Complex sphingolipids, such as IPC and SM, are
major components of the outer leaﬂet of eukaryotic
plasma membranes that are thought to be involved,
together with sterols, in the formation of micro-
domains known as lipid rafts. These rafts have been
proposed to function in a diverse array of processes
from the polarised traﬃcking of lipid-modiﬁed pro-
teins, to the assembly and activation of signal trans-
duction complexes (Simons and Ikonen, 1997). The
non-mammalian nature of IPC synthase makes it an
attractive drug target, and it has been validated as
such in both the pathogenic fungi and the kineto-
plastid protozoa (Georgopapadakou, 2000; Hanada,
2005; Mina et al. 2009, 2010).
Toxoplasma gondii is an obligate, intracellular
protozoan parasite, able to invade and colonize a
wide variety of nucleated vertebrate cells. It is a
member of the Apicomplexa, a diverse phylum
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including important pathogens of domestic animals
and humans such as Eimeria (the etiological agent
of coccidiosis in poultry), Theileria (East Coast
Fever in Cattle), Cryptosporidium (diarrhoea) and
Plasmodium (malaria). In common with other api-
complexans Toxoplasma has a complex lifecycle,
involving a deﬁnitive, feline, host; and both rapidly
proliferative, tachyzoite forms (all tissues in acute
disease) and slowly dividing, bradyzoite forms
(muscle and brain tissue cysts in chronic disease)
(Dubey, 1977). Toxoplasma is an opportunistic
pathogen and is a signiﬁcant cause of disease (toxo-
plasmosis) in the immunocompromised: particularly
organ transplant recipients, those receiving anti-
cancer chemotherapy and AIDS patients (Chowdhury,
1986). In utero toxoplasmosis is also a signiﬁcant cause
of congenital defects in humans (Chowdhury, 1986)
and spontaneous abortion in economically important
domestic animals (Dubey, 1977). The diseases listed
above are associated with rapidly dividing, tachyzoite
Toxoplasma, either directly acquired or the result of
the reactivation of a chronic infection. However, in
addition, bradyzoite, chronic, toxoplasmosis has
been associated with psychiatric disorders, including
schizophrenia (Webster et al. 2013). The drugs
available for acute toxoplasmosis (tachyzoite stage)
have various problems with eﬃcacy and safety, fur-
thermore no treatments are available for chronic
disease (encysted bradyzoite stage) therefore new
therapies are urgently required (Antczak et al. 2016).
The synthesis of IPC by Toxoplasma was ﬁrst
reported on the basis of metabolic labelling ex-
periments (Sonda et al. 2005) and subsequently
conﬁrmed using directed mass spectrometry (Pratt
et al. 2013). In addition, inhibition of parasite IPC
synthesis by AbA was indicated and the tractability
of this natural compound as a new lead proposed
(Sonda et al. 2005; Coppens, 2013). Utilising AbA
and the availability of a well characterized ortholo-
gue with improved pharmacokinetic properties,
Compound 20 (Fig. 1, modiﬁed with a pyridyl
group at AbA position 4; Wuts et al. 2015), here
we examine the eﬀect of these compounds on
the Toxoplasma AUR1 orthologue (TgSLS; (Pratt
et al. 2013) and total sphingolipid biosynthesis;
and on the proliferation of both tachyzoite and bra-
dyzoite form parasites. The results demonstrate that
whilst both compounds inhibit the proliferation of
Toxoplasma, neither inhibits TgSLS nor total
sphingolipid biosynthesis as previously proposed
(Sonda et al. 2005; Coppens, 2013). However,
despite uncertainty regarding the mode of action,
the ability of this class of cyclic depsipeptides to
clear encysted bradyzoite-like form Toxoplasma
from infected tissue culture cells marks them as a
possibly unique therapy for chronic toxoplasmosis.
MATERIALS AND METHODS
Cell culture
Toxoplasma gondii (strains RH-TATi-1 (Meissner
et al. 2002), RH-HX-KO-YFP2-DHFR (Gubbels
et al. 2003) and Pru-GRA2-GFP-DHFR (Kim et al.
2007) were maintained in Vero, Human Foreskin
Fibroblast (HFF) or Chinese Hamster Ovary
(CHO) cells grown in DMEM (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS) at 37 °C
and 5% CO2. Type IIToxoplasma (Pru strain) tachy-
zoites were diﬀerentiated to the bradyzoite-like form
in HFF cells via an alkaline shift to pH8 as previ-
ously described (Soete et al. 1994).
Metabolic labelling
Saccharomoyces cerevisiae and Vero cells were
labelled with 5 µM of NBD C6-ceramide complexed
with Bovine Serum Albumin (BSA) (Invitrogen)
for use as controls as previously (Denny et al.
2006). Toxoplasma tachyzoites were separated from
host cell material by ﬁltration through 3 and 5 mm
polycarbonate ﬁlters (Millipore) after disruption by
passage through a narrow gauge needle. Released
parasites were then isolated by centrifugation at
Fig. 1. The structures of the cyclic depsipeptide
compounds Aureobasidin A and its analogue Compound
20 (Wuts et al. 2015).
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1430 g for 15 min at room temperature, washed and
resuspended in serum-free DMEM (Invitrogen) at
107 mL−1 and incubated for 1 h at 37 °C before the
addition of NBD C6-ceramide complexed with BSA
to 5 µM, and a further 1 h at 37 °C. For the inhibitor
studies, AbA or Compound 20 were added to isolated
Toxoplasma at 10 µg mL−1 and incubated at 37 °C for
1, 4 or 7 h, before the addition of NBD C6-ceramide
complexed with BSA to 5 µM and a further incubation
at 37 °C for 1 h. Lipids were extracted and analysed
by HPTLC as previously described (Mina et al.
2009).
Toxoplasma susceptibility assay
HFF cells were seeded at 104 cells per well in 96 well
microtitre plates (Nunc). After 18 h at 37 °C isolated
Toxoplasma RH-HX-KO-YFP2-DHFR (Gubbels
et al. 2003) were inoculated into the host cells at
6250 parasites per well. Following a further 20 h
incubation compounds were added at the appropri-
ate concentrations. In an additional experiment, iso-
lated tachyzoite parasites were pre-treated with
compounds for 2 and 8 h, then washed, prior to
infection of HFF cells. For bradyzoite assays, the
Toxoplasma Pru-GRA2-GFP-DHFR (Kim et al.
2007) tachyzoites were added at the same concentra-
tion but then transformed as described (Soete et al.
1994) before the addition of the compounds. Plates
were washed after 2 or 8 h, or not, as described in
text. The plates were read using a Biotek Synergy
H4 plate reader (Ex 510 nm; Em 540 nm) after 6
or 3 days, respectively.
Yeast susceptibility assay
YPH499-HIS-GAL-AUR1 (a yeast strain in which
expression of the essential IPC synthase, AUR1p, is
under the control of a galactose promoter) comple-
mented with TgSLS or AUR1 (Denny et al. 2006;
Pratt et al. 2013) were assayed for susceptibility to
AbA and Compound 20. The transgenic yeast
strains were maintained on SD -HIS -URA agar
(0·17% Bacto yeast nitrogen base, 0·5% ammonium
sulphate, 2% glucose, containing the appropriate
nutritional supplements) at 30 °C. To analyse sus-
ceptibility to AbA and Compound 20 plates contain-
ing 5 or 10 µg mL−1 of the compound were prepared
and 10 µL of an aqueous suspension of yeast spotted
onto the surface before incubation at 30 °C.
Transcript analyses
For the mRNA analyses, total RNA from equivalent
numbers of CHO cells infected for 72 h with
Toxoplasma RH-TATi parasites, or non-infected,
was extracted using the RNeasy kit (Qiagen) according
to the manufacturer’s protocol. Following DNase
treatment (RQ1, Promega) cDNA was synthesized
using the ImProm-II Reverse Transcription System
(Promega) according to manufacturer’s protocol.
Quantitative PCR (qPCR) was performed in a
RotorGene® RG3000 (Corbett Research) using
SYBR Green Jump-Start Taq Ready Mix (Sigma
Aldrich) according to the manufacturer’s instructions.
The hamster, Cricetulus griseus, CgLcb2 (encoding
subunit 2 of SPT) was ampliﬁed using the primer
pair – 5′CAGACAACTTTGTTTTCGG3′ and
5′GGGTGGCATTGTAGGGC3′. The reference
gene, CgβTub, was ampliﬁed using the primer pair –
5′TAAAACGACGGCCAGTGAGC3′ and 5′TCT
CCTGGCGAGTGCTGC3′. The qPCR was carried
out in triplicate on 3 replicates with an annealing
temperature 55°C for CgLcb2 and CgβTub.
RESULTS
Comparing the eﬀect of AbA and its analogue
Compound 20 on the proliferation of the Toxoplasma
tachyzoite form
AbA has previously been shown to inhibit the prolif-
eration of the rapidly dividing, tachyzoite form of
Toxoplasma. The eﬀective concentration of com-
pound reducing proliferation by 50% (ED50) was
calculated as 0·3 µg mL−1 by cell counting 48 h
post infection and 46 h post addition of AbA
(Sonda et al. 2005). In order to gain a more rapid
and robust dataset to facilitate comparative analyses
of the eﬃcacy of AbA and Compound 20 we utilised
the availability of the yellow ﬂuorescent protein
labelled Toxoplasma, RH-strain (Gubbels et al.
2003). Gubbels et al. demonstrated the tractability
of this system by comparison with β-galactosidase
producing parasites. Following validation and par-
ameter setting (data not shown), HFF cells were
plated onto 96-well plates and infected with 6250
Toxoplasma per well as described in the section
Materials and Methods. After 20 h the compounds
were added and, without washing, the plate incu-
bated for 144 h (6 days) before ﬂuorescent readings
were taken. Following data analyses the ED50 was
calculated as described (Fig. 2). As can been seen
both AbA and Compound 20 showed activity
against Toxoplasma RH tachyzoites. However, the
parent compound (ED50 of 0·75, 95% CI 0·60 to
0·93 µg mL−1) was slightly more eﬃcacious than
its derivative (ED50 of 1·49, 95% CI 1·20 to
1·85 µg mL−1). This diﬀerential activity was even
more evident on further analyses. Previously, using
an indirect assay (vacuole formation), it has been indi-
cated that the eﬃcacy of AbA against Toxoplasma is
partially reversible after 24, but not 48 h, exposure
(Sonda et al. 2005). To further analyse the revers-
ibility of the eﬃcacy of cyclic depsipeptides, the
infected HFF cells were washed following 2 and
8 h of compound treatment and proliferation then
followed for 6 days as previously (Fig. 2). In
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keeping with Sonda et al. (2005) eﬃcacy was par-
tially reversible, but Toxoplasma were clearly sus-
ceptible to AbA in an 8 h treatment (ED50 of 4·82,
95% CI 3·73 to 6·22 µg mL−1), and even 2 h expos-
ure demonstrated some activity (ED50 of 9·58, 95%
CI 6·66 to 13·76 µg mL−1). However, in contrast,
the activity of Compound 20 was demonstrated to
be almost completely reversible under the conditions
employed.
Interestingly, the unrelated kinetoplastid proto-
zoa, Trypanosoma cruzi (the causative agent of
American Trypanosomiasis or Chagas disease) has
Fig. 2. ED50 of Aureobasidin A (AbA, A-D) or Compound 20 (Cpmd 20, E-H) – μg mL
−1; (95% Conﬁdence Interval) –
against the Toxoplasma RH tachyzoite form in HFF cells. 6 days post addition of the compounds. In agreement with
Sonda et al. (2005), both compounds were non-toxic to HHF cells under the conditions employed. A and B: no wash out
post-compound addition; C and D: wash out 2 h post-compound addition; E and F: wash out 8 h post-compound
addition; G and H: 2 h pre-treatment of isolated parasites pre-infection. Calculated using GraphPad Prism 7, log
(inhibitor) vs normalized response – Variable slope. >10 µg mL−1 – ED50 could not be determined. Representative in
triplicate dataset.
4A. Q. I. Alqaisi and others
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182017000506
Downloaded from https:/www.cambridge.org/core. Durham University Library, on 15 May 2017 at 12:32:30, subject to the Cambridge Core terms of use, available at
also been shown to be sensitive to AbA, with the IPC
synthase again proposed as the target (Salto et al.
2003). However, enzyme analyses did not conﬁrm
this and it was suggested that the compound acts
on the host to promote clearance of the parasite
(Figueiredo et al. 2005). In order to test this hypoth-
esis in Toxoplasma infection, tachyzoite parasites
were isolated from infected cells as described in the
section Materials and Methods and then treated
with various concentrations of AbA and Compound
20 prior to washing and infecting host HFF cells. A
2 h treatment again demonstrated that AbA was
eﬀective (ED50 of 4·78, 95% CI 3·95 to 5·79 µg
mL−1), whilst the analogue was inactive (Fig. 2).
Longer periods post-isolation (8 h) lead to untreated
parasites losing infectivity.
The sensitivity of the Toxoplasma gondii sphingolipid
synthase and sphingolipid synthesis per se to AbA and
its analogue Compound 20
Host sphingolipid biosynthesis is unaﬀected by
(Fig. S1) and non-essential for (Pratt et al. 2013;
Romano et al. 2013), Toxoplasma proliferation.
Therefore, de novo synthesis of sphingolipids is an
attractive target for new antiprotozoal drug leads.
The antifungal sphingolipid (IPC) synthase inhibitor
AbA has been proposed to inhibit the Toxoplasma
orthologue (Sonda et al. 2005; Coppens, 2013).
However, analyses of an enzyme isolated from
Toxoplasma demonstrating IPC synthase activity
(TgSLS) did not support this conclusion (Pratt
et al. 2013). Utilizing the previously constructed,
auxotropic, TgSLS complemented yeast strains
(YPH499-HIS-GAL-AUR1 pRS426 TgSLS, with
YPH499-HIS-GAL-AUR1 pRS426 AUR1 as a
control), the sensitivity of the protozoan enzyme to
AbA and Compound 20 was analysed (Fig. 3). The
results clearly demonstrated that the Toxoplasma
enzyme conferred resistance to yeast against both
cyclic depsipeptides at concentrations lethal to
yeast reliant on AUR1 activity (5 and 10 µg mL−1).
However, whilst TgSLS clearly functions as an
IPC synthase in yeast and in vitro, Toxoplasma
have also been demonstrated, by the incorporation
of tritiated serine, to synthesize sphingomyelin
(SM) and glycosphingolipids (GSLs) (Gerold and
Schwarz, 2001). The presence of SM and GSLs in
isolated Toxoplasma was subsequently conﬁrmed
using mass spectrometry (Welti et al. 2007; Pratt
et al. 2013). In addition, relatively high levels of
ethanolamine phosphorylceramide (EPC), a non-
abundant species in mammalian cells, were also
reported (Welti et al. 2007; Pratt et al. 2013). In
light of this synthetic complexity, and the potential
of enzymatic diversity, the eﬀect of AbA and
Compound 20 on total sphingolipid biosynthesis in
Toxoplasma was investigated. Labelling isolated
Toxoplasma with NBD-C6−ceramide as described
in the section Materials and Methods demonstrated
that the parasite synthesized a complex of sphingo-
lipid species, including SM and EPC (co-migrating
with mammalian equivalents; Vacaru et al. 2013).
However, IPC was not evident and 2 other species
(X and Y) remain unassigned (Fig. 4). The addition
of AbA and Compound 20 at 10 µg mL−1 for 1, 4
and 7 h, before 1 h NBD-C6−ceramide labelling,
had no eﬀect on the synthesis of the sphingolipids
compared with controls (Fig. 5). This demonstrated
that this class of cyclic depsipeptides do not exert
their activity through inhibition or dysregulation
of sphingolipid biosynthesis. However, it is notable
that the complex sphingolipid proﬁle produced
does change as the time post parasite isolation
increases, with the levels of labelled lipids X and Y
increased at 4 and 7 h, EPC levels decreased and
SM levels unchanged (Fig. 5). This indicated that
the stress of isolation from the host cell leads to
the modiﬁcation sphingolipid biosynthesis or to
catabolism.
Comparing the eﬃcacy of AbA and its analogue
Compound 20 against the encysted Toxoplasma
bradyzoite form
With a complete lack of treatments available for
chronic disease, in which Toxoplasma has reached
the encysted bradyzoite stage, new therapies are
urgently needed (Antczak et al. 2016). Therefore,
although the mode of action of the cyclic depsipep-
tides remains unclear, the eﬃcacy of these com-
pounds against the encysted form of the parasite
was analysed. Utilizing the Type II Pru strain of
Toxoplasma modiﬁed to express GFP (Kim et al.
2007) we analysed the eﬃcacy of AbA and
Compound 20 against HFF cells infected with para-
sites transformed into a bradyzoite-like stage using
an established protocol (Soete et al. 1994). Following
3 days of exposure, both compounds demonstrated
promising activity against the encysted Toxoplasma
(Fig. 6), again AbA demonstrated slightly higher
eﬃcacy (ED50 of 2·51, 95% CI 1·96 to 3·23 µg mL
−1)
than Compound 20 (ED50 of 3·74, 95% CI 3·13 to
4·47 µg mL−1). This showed that the cyclic depsipep-
tides may represent promising candidates for therapies
to treat both acute and chronic toxoplasmosis.
DISCUSSION
Toxoplasma is an important cause of disease in
humans and domestic animals. Whilst there are
several drugs available to treat acute (tachyzoite
stage) toxoplasmosis, there is a complete absence of
eﬀective therapies for chronic disease (encysted bra-
dyzoite stage; Antczak et al. 2016). It has been
demonstrated that Toxoplasma remain able to repli-
cate in CHO cells where the activity of the ﬁrst and
rate limiting step in sphingolipid biosythesis, serine
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palmitoyltransferase (SPT), was greatly reduced
and complex sphinglipid levels consequently
lowered (Hanada et al. 1992; Pratt et al. 2013). In
addition, in this study we showed that key enzymes
in host (CHO) sphingolipid biosynthesis are unaﬀected
by Toxoplasma infection (Fig. S1). Together, these
data indicated that targeting the de novo Toxoplasma
sphingolipid biosynthetic pathway could represent a
viable strategy towards the identiﬁcation of new
antiprotozoals. A strategy that could also be applic-
able to other apicomplexan parasites such as
Plasmodium spp. (Lauer et al. 1995), and one that
has is already being investigated for kinetoplastid
protozoan pathogens (Denny et al. 2006; Mina
et al. 2009, 2010, 2011).
To these ends it has been suggested that the anti-
fungal cyclic depsipeptide, AbA exerts its eﬀect on
Toxoplasma by inhibiting a sphinglipid (IPC) syn-
thase, an orthologue of its validated target in yeast
(Nagiec et al. 1997; Sonda et al. 2005). Given the
status of the fungal and kinetoplastid IPC synthases
as promising drug targets (Young et al. 2012), the
identiﬁcation of the Toxoplasma orthologue (Pratt
et al. 2013) led to its consideration as a target for
anti-apicomplexan drugs. TgSLS functions as an
IPC synthase and the product was identiﬁed in para-
site extracts using directed mass spectrometry.
However, AbA was demonstrated to be non-active
against the enzyme activity in vitro (Pratt et al.
2013).
To investigate this compound class further, here
we utilized the availability of AbA and a synthetic-
ally modiﬁed analogue, Compound 20 (Wuts et al.
2015), to test the eﬃcacy and mode of action of
these cyclic depsipeptides against Toxoplasma. As
expected, neither compound inhibited the growth
of transgenic yeast dependent on the expression of
TgSLS (Fig. 3). Furthermore, the compounds also
exhibited no eﬀect on the synthesis of complex
sphingolipids in Toxoplasma (Fig. 5). Interestingly,
no IPC synthesis was apparent indicating that this
activity may be low, in tachyzoites at least.
However, both SM and EPC (Azzouz et al. 2002;
Welti et al. 2007) were clearly produced, as well as
2 uncharacterised complex sphingolipids (Fig. 4).
However, despite this lack of dysregulation of
sphingolipid biosythesis, both AbA and Compound
20 are active against the tachyzoite form of the parasite
in infected HHF cells. AbA exhibited greater eﬃcacy
and, unlike Compound 20, demonstrated a rapid and
direct ‘cidal activity against the Toxoplasma parasite
(Fig. 2). Furthermore, and importantly, both AbA
and Compound 20 clear encysted bradyzoite-like
Fig. 3. Yeast dependent on the expression of the
Toxoplasma AUR1p orthologue TgSLS (YPH499-
HIS-GAL-AUR1 pRS426 TgSLS) are resistant to
Aureobasidin A (AbA) and Compound 20 (Cmpd 20) at
5 and 10 µg mL−1. This contrasts to the sensitivity of
yeast dependent on AUR1 expression (YPH499-HIS-
GAL-AUR1 pRS426 AUR1).
Fig. 4. Vero cells (Host), isolated Toxoplasma tachyzoites
(Toxo) and Saccharomyces cerevisiae (Yeast), labelled for
1 h with NBD-C6-ceramide and complex sphingolipids
then fractionated by HPTLC. Like the host cells,
Toxoplasma parasites synthesize sphingomyelin
(SM) and ethanolamine phosphorylceramide (EPC),
two unique sphingolipids are also produced (X and Y).
However, unlike in S. cerevisiae, no labelled
inositol phosphorylceramide (IPC) is evident from
either host or Toxoplasma cells. Representative
dataset.
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form Toxoplasma from infected tissue culture at low
concentrations (Fig. 6). Given the well established
lack of toxicity of these compounds to mammalian
cells, coupled with the promising pharmacokinetic
properties of Compound 20 (Wuts et al. 2015), this
class of cyclic depsipeptides may form the basis of
a unique therapy for chronic toxoplasmosis and
perhaps, some psychiatric disorders.
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